img

Global Neurodegenerative Disease Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neurodegenerative Disease Market Insights, Forecast to 2034

Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, leading to cognitive and motor impairments. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Market Analysis and InsightsGlobal Neurodegenerative Disease Market
Global Neurodegenerative Disease market is expected to reach to US$ 7239.3 million in 2024, with a positive growth of %, compared with US$ 7003.2 million in 2022. Backed with the increasing demand from downstream industries, Neurodegenerative Disease industry is evaluated to reach US$ 8704 million in 2029. The CAGR will be 3.1% during 2024 to 2029.
The market for neurodegenerative disease treatments and management is driven by the increasing prevalence of these diseases, particularly with an aging population. The market's growth is also influenced by the demand for disease-modifying therapies and symptom management options to improve the quality of life for patients.
Report Covers
This report presents an overview of global Neurodegenerative Disease market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Neurodegenerative Disease market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Segment by Type
NMDA
SSRIs
Dopamine Inhibitors

Segment by Application


Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Neurodegenerative Disease introduction, etc. Neurodegenerative Disease Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Neurodegenerative Disease
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease Market Perspective (2018-2029)
2.2 Global Neurodegenerative Disease Growth Trends by Region
2.2.1 Neurodegenerative Disease Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neurodegenerative Disease Historic Market Size by Region (2018-2024)
2.2.3 Neurodegenerative Disease Forecasted Market Size by Region (2024-2029)
2.3 Neurodegenerative Disease Market Dynamics
2.3.1 Neurodegenerative Disease Industry Trends
2.3.2 Neurodegenerative Disease Market Drivers
2.3.3 Neurodegenerative Disease Market Challenges
2.3.4 Neurodegenerative Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Neurodegenerative Disease by Players
3.1.1 Global Neurodegenerative Disease Revenue by Players (2018-2024)
3.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2018-2024)
3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Neurodegenerative Disease, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Neurodegenerative Disease Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2022
3.5 Global Key Players of Neurodegenerative Disease Head office and Area Served
3.6 Global Key Players of Neurodegenerative Disease, Product and Application
3.7 Global Key Players of Neurodegenerative Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disease Breakdown Data by Type
4.1 Global Neurodegenerative Disease Historic Market Size by Type (2018-2024)
4.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2029)
5 Neurodegenerative Disease Breakdown Data by Application
5.1 Global Neurodegenerative Disease Historic Market Size by Application (2018-2024)
5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Neurodegenerative Disease Market Size (2018-2029)
6.2 North America Neurodegenerative Disease Market Size by Type
6.2.1 North America Neurodegenerative Disease Market Size by Type (2018-2024)
6.2.2 North America Neurodegenerative Disease Market Size by Type (2024-2029)
6.2.3 North America Neurodegenerative Disease Market Share by Type (2018-2029)
6.3 North America Neurodegenerative Disease Market Size by Application
6.3.1 North America Neurodegenerative Disease Market Size by Application (2018-2024)
6.3.2 North America Neurodegenerative Disease Market Size by Application (2024-2029)
6.3.3 North America Neurodegenerative Disease Market Share by Application (2018-2029)
6.4 North America Neurodegenerative Disease Market Size by Country
6.4.1 North America Neurodegenerative Disease Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Neurodegenerative Disease Market Size by Country (2018-2024)
6.4.3 North America Neurodegenerative Disease Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Market Size (2018-2029)
7.2 Europe Neurodegenerative Disease Market Size by Type
7.2.1 Europe Neurodegenerative Disease Market Size by Type (2018-2024)
7.2.2 Europe Neurodegenerative Disease Market Size by Type (2024-2029)
7.2.3 Europe Neurodegenerative Disease Market Share by Type (2018-2029)
7.3 Europe Neurodegenerative Disease Market Size by Application
7.3.1 Europe Neurodegenerative Disease Market Size by Application (2018-2024)
7.3.2 Europe Neurodegenerative Disease Market Size by Application (2024-2029)
7.3.3 Europe Neurodegenerative Disease Market Share by Application (2018-2029)
7.4 Europe Neurodegenerative Disease Market Size by Country
7.4.1 Europe Neurodegenerative Disease Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Neurodegenerative Disease Market Size by Country (2018-2024)
7.4.3 Europe Neurodegenerative Disease Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Neurodegenerative Disease Market Size (2018-2029)
8.2 China Neurodegenerative Disease Market Size by Type
8.2.1 China Neurodegenerative Disease Market Size by Type (2018-2024)
8.2.2 China Neurodegenerative Disease Market Size by Type (2024-2029)
8.2.3 China Neurodegenerative Disease Market Share by Type (2018-2029)
8.3 China Neurodegenerative Disease Market Size by Application
8.3.1 China Neurodegenerative Disease Market Size by Application (2018-2024)
8.3.2 China Neurodegenerative Disease Market Size by Application (2024-2029)
8.3.3 China Neurodegenerative Disease Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Neurodegenerative Disease Market Size (2018-2029)
9.2 Asia Neurodegenerative Disease Market Size by Type
9.2.1 Asia Neurodegenerative Disease Market Size by Type (2018-2024)
9.2.2 Asia Neurodegenerative Disease Market Size by Type (2024-2029)
9.2.3 Asia Neurodegenerative Disease Market Share by Type (2018-2029)
9.3 Asia Neurodegenerative Disease Market Size by Application
9.3.1 Asia Neurodegenerative Disease Market Size by Application (2018-2024)
9.3.2 Asia Neurodegenerative Disease Market Size by Application (2024-2029)
9.3.3 Asia Neurodegenerative Disease Market Share by Application (2018-2029)
9.4 Asia Neurodegenerative Disease Market Size by Region
9.4.1 Asia Neurodegenerative Disease Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Neurodegenerative Disease Market Size by Region (2018-2024)
9.4.3 Asia Neurodegenerative Disease Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type
10.2.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application
10.3.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country
10.4.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurodegenerative Disease Introduction
11.1.4 Novartis Revenue in Neurodegenerative Disease Business (2018-2024)
11.1.5 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Disease Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Disease Business (2018-2024)
11.2.5 Pfizer Recent Developments
11.3 Merck Serono
11.3.1 Merck Serono Company Details
11.3.2 Merck Serono Business Overview
11.3.3 Merck Serono Neurodegenerative Disease Introduction
11.3.4 Merck Serono Revenue in Neurodegenerative Disease Business (2018-2024)
11.3.5 Merck Serono Recent Developments
11.4 Biogen Idec
11.4.1 Biogen Idec Company Details
11.4.2 Biogen Idec Business Overview
11.4.3 Biogen Idec Neurodegenerative Disease Introduction
11.4.4 Biogen Idec Revenue in Neurodegenerative Disease Business (2018-2024)
11.4.5 Biogen Idec Recent Developments
11.5 TEVA
11.5.1 TEVA Company Details
11.5.2 TEVA Business Overview
11.5.3 TEVA Neurodegenerative Disease Introduction
11.5.4 TEVA Revenue in Neurodegenerative Disease Business (2018-2024)
11.5.5 TEVA Recent Developments
11.6 UCB
11.6.1 UCB Company Details
11.6.2 UCB Business Overview
11.6.3 UCB Neurodegenerative Disease Introduction
11.6.4 UCB Revenue in Neurodegenerative Disease Business (2018-2024)
11.6.5 UCB Recent Developments
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Details
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Disease Introduction
11.7.4 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2018-2024)
11.7.5 Boehringer Ingelheim Recent Developments
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Neurodegenerative Disease Introduction
11.8.4 Sanofi Revenue in Neurodegenerative Disease Business (2018-2024)
11.8.5 Sanofi Recent Developments
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Neurodegenerative Disease Introduction
11.9.4 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2018-2024)
11.9.5 GlaxoSmithKline Recent Developments
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Details
11.10.2 Livzon Pharmaceutical Business Overview
11.10.3 Livzon Pharmaceutical Neurodegenerative Disease Introduction
11.10.4 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.10.5 Livzon Pharmaceutical Recent Developments
11.11 Haisco Pharmaceutical
11.11.1 Haisco Pharmaceutical Company Details
11.11.2 Haisco Pharmaceutical Business Overview
11.11.3 Haisco Pharmaceutical Neurodegenerative Disease Introduction
11.11.4 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.11.5 Haisco Pharmaceutical Recent Developments
11.12 Jingxin Pharmaceutical
11.12.1 Jingxin Pharmaceutical Company Details
11.12.2 Jingxin Pharmaceutical Business Overview
11.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Introduction
11.12.4 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.12.5 Jingxin Pharmaceutical Recent Developments
11.13 Dongcheng Biochemicals
11.13.1 Dongcheng Biochemicals Company Details
11.13.2 Dongcheng Biochemicals Business Overview
11.13.3 Dongcheng Biochemicals Neurodegenerative Disease Introduction
11.13.4 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2018-2024)
11.13.5 Dongcheng Biochemicals Recent Developments
11.14 Hisun Pharmaceutical
11.14.1 Hisun Pharmaceutical Company Details
11.14.2 Hisun Pharmaceutical Business Overview
11.14.3 Hisun Pharmaceutical Neurodegenerative Disease Introduction
11.14.4 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.14.5 Hisun Pharmaceutical Recent Developments
11.15 Luye Pharma
11.15.1 Luye Pharma Company Details
11.15.2 Luye Pharma Business Overview
11.15.3 Luye Pharma Neurodegenerative Disease Introduction
11.15.4 Luye Pharma Revenue in Neurodegenerative Disease Business (2018-2024)
11.15.5 Luye Pharma Recent Developments
11.16 Ark Pharmaceutical
11.16.1 Ark Pharmaceutical Company Details
11.16.2 Ark Pharmaceutical Business Overview
11.16.3 Ark Pharmaceutical Neurodegenerative Disease Introduction
11.16.4 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.16.5 Ark Pharmaceutical Recent Developments
11.17 Kanghong Pharmaceutical
11.17.1 Kanghong Pharmaceutical Company Details
11.17.2 Kanghong Pharmaceutical Business Overview
11.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Introduction
11.17.4 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.17.5 Kanghong Pharmaceutical Recent Developments
11.18 Huahai Pharmaceutical
11.18.1 Huahai Pharmaceutical Company Details
11.18.2 Huahai Pharmaceutical Business Overview
11.18.3 Huahai Pharmaceutical Neurodegenerative Disease Introduction
11.18.4 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024)
11.18.5 Huahai Pharmaceutical Recent Developments
11.19 BORA PHARMACEUTICALS
11.19.1 BORA PHARMACEUTICALS Company Details
11.19.2 BORA PHARMACEUTICALS Business Overview
11.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Introduction
11.19.4 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2018-2024)
11.19.5 BORA PHARMACEUTICALS Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of NMDA
Table 3. Key Players of SSRIs
Table 4. Key Players of Dopamine Inhibitors
Table 5. Global Neurodegenerative Disease Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global Neurodegenerative Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Neurodegenerative Disease Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global Neurodegenerative Disease Market Share by Region (2018-2024)
Table 9. Global Neurodegenerative Disease Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Neurodegenerative Disease Market Share by Region (2024-2029)
Table 11. Neurodegenerative Disease Market Trends
Table 12. Neurodegenerative Disease Market Drivers
Table 13. Neurodegenerative Disease Market Challenges
Table 14. Neurodegenerative Disease Market Restraints
Table 15. Global Neurodegenerative Disease Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global Neurodegenerative Disease Revenue Share by Players (2018-2024)
Table 17. Global Top Neurodegenerative Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Table 18. Global Neurodegenerative Disease Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of Neurodegenerative Disease, Headquarters and Area Served
Table 21. Global Key Players of Neurodegenerative Disease, Product and Application
Table 22. Global Key Players of Neurodegenerative Disease, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global Neurodegenerative Disease Revenue Market Share by Type (2018-2024)
Table 26. Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Neurodegenerative Disease Revenue Market Share by Type (2024-2029)
Table 28. Global Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global Neurodegenerative Disease Revenue Share by Application (2018-2024)
Table 30. Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Neurodegenerative Disease Revenue Share by Application (2024-2029)
Table 32. North America Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America Neurodegenerative Disease Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America Neurodegenerative Disease Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America Neurodegenerative Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe Neurodegenerative Disease Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe Neurodegenerative Disease Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe Neurodegenerative Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 46. China Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 47. China Neurodegenerative Disease Market Size by Type (2024-2029) & (US$ Million)
Table 48. China Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 49. China Neurodegenerative Disease Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia Neurodegenerative Disease Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia Neurodegenerative Disease Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia Neurodegenerative Disease Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia Neurodegenerative Disease Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia Neurodegenerative Disease Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Neurodegenerative Disease Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 64. Novartis Company Details
Table 65. Novartis Business Overview
Table 66. Novartis Neurodegenerative Disease Product
Table 67. Novartis Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 68. Novartis Recent Developments
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Neurodegenerative Disease Product
Table 72. Pfizer Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 73. Pfizer Recent Developments
Table 74. Merck Serono Company Details
Table 75. Merck Serono Business Overview
Table 76. Merck Serono Neurodegenerative Disease Product
Table 77. Merck Serono Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 78. Merck Serono Recent Developments
Table 79. Biogen Idec Company Details
Table 80. Biogen Idec Business Overview
Table 81. Biogen Idec Neurodegenerative Disease Product
Table 82. Biogen Idec Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 83. Biogen Idec Recent Developments
Table 84. TEVA Company Details
Table 85. TEVA Business Overview
Table 86. TEVA Neurodegenerative Disease Product
Table 87. TEVA Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 88. TEVA Recent Developments
Table 89. UCB Company Details
Table 90. UCB Business Overview
Table 91. UCB Neurodegenerative Disease Product
Table 92. UCB Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 93. UCB Recent Developments
Table 94. Boehringer Ingelheim Company Details
Table 95. Boehringer Ingelheim Business Overview
Table 96. Boehringer Ingelheim Neurodegenerative Disease Product
Table 97. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 98. Boehringer Ingelheim Recent Developments
Table 99. Sanofi Company Details
Table 100. Sanofi Business Overview
Table 101. Sanofi Neurodegenerative Disease Product
Table 102. Sanofi Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 103. Sanofi Recent Developments
Table 104. GlaxoSmithKline Company Details
Table 105. GlaxoSmithKline Business Overview
Table 106. GlaxoSmithKline Neurodegenerative Disease Product
Table 107. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 108. GlaxoSmithKline Recent Developments
Table 109. Livzon Pharmaceutical Company Details
Table 110. Livzon Pharmaceutical Business Overview
Table 111. Livzon Pharmaceutical Neurodegenerative Disease Product
Table 112. Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 113. Livzon Pharmaceutical Recent Developments
Table 114. Haisco Pharmaceutical Company Details
Table 115. Haisco Pharmaceutical Business Overview
Table 116. Haisco Pharmaceutical Neurodegenerative Disease Product
Table 117. Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 118. Haisco Pharmaceutical Recent Developments
Table 119. Jingxin Pharmaceutical Company Details
Table 120. Jingxin Pharmaceutical Business Overview
Table 121. Jingxin Pharmaceutical Neurodegenerative Disease Product
Table 122. Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 123. Jingxin Pharmaceutical Recent Developments
Table 124. Dongcheng Biochemicals Company Details
Table 125. Dongcheng Biochemicals Business Overview
Table 126. Dongcheng Biochemicals Neurodegenerative Disease Product
Table 127. Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 128. Dongcheng Biochemicals Recent Developments
Table 129. Hisun Pharmaceutical Company Details
Table 130. Hisun Pharmaceutical Business Overview
Table 131. Hisun Pharmaceutical Neurodegenerative Disease Product
Table 132. Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 133. Hisun Pharmaceutical Recent Developments
Table 134. Luye Pharma Company Details
Table 135. Luye Pharma Business Overview
Table 136. Luye Pharma Neurodegenerative Disease Product
Table 137. Luye Pharma Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 138. Luye Pharma Recent Developments
Table 139. Ark Pharmaceutical Company Details
Table 140. Ark Pharmaceutical Business Overview
Table 141. Ark Pharmaceutical Neurodegenerative Disease Product
Table 142. Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 143. Ark Pharmaceutical Recent Developments
Table 144. Kanghong Pharmaceutical Company Details
Table 145. Kanghong Pharmaceutical Business Overview
Table 146. Kanghong Pharmaceutical Neurodegenerative Disease Product
Table 147. Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 148. Kanghong Pharmaceutical Recent Developments
Table 149. Huahai Pharmaceutical Company Details
Table 150. Huahai Pharmaceutical Business Overview
Table 151. Huahai Pharmaceutical Neurodegenerative Disease Product
Table 152. Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 153. Huahai Pharmaceutical Recent Developments
Table 154. BORA PHARMACEUTICALS Company Details
Table 155. BORA PHARMACEUTICALS Business Overview
Table 156. BORA PHARMACEUTICALS Neurodegenerative Disease Product
Table 157. BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2018-2024) & (US$ Million)
Table 158. BORA PHARMACEUTICALS Recent Developments
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Neurodegenerative Disease Market Share by Type: 2022 VS 2029
Figure 3. NMDA Features
Figure 4. SSRIs Features
Figure 5. Dopamine Inhibitors Features
Figure 6. Global Neurodegenerative Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Neurodegenerative Disease Market Share by Application: 2022 VS 2029
Figure 8. Parkinson’s Disease Case Studies
Figure 9. Huntington Disease Case Studies
Figure 10. Amyotrophic Lateral Sclerosis Case Studies
Figure 11. Alzheimer’s Disease Case Studies
Figure 12. Neurodegenerative Disease Report Years Considered
Figure 13. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Neurodegenerative Disease Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Neurodegenerative Disease Market Share by Region: 2022 VS 2029
Figure 16. Global Neurodegenerative Disease Market Share by Players in 2022
Figure 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2022
Figure 19. North America Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Neurodegenerative Disease Market Share by Type (2018-2029)
Figure 21. North America Neurodegenerative Disease Market Share by Application (2018-2029)
Figure 22. North America Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 23. United States Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Neurodegenerative Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Neurodegenerative Disease Market Share by Type (2018-2029)
Figure 27. Europe Neurodegenerative Disease Market Share by Application (2018-2029)
Figure 28. Europe Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 29. Germany Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Neurodegenerative Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Neurodegenerative Disease Market Share by Type (2018-2029)
Figure 37. China Neurodegenerative Disease Market Share by Application (2018-2029)
Figure 38. Asia Neurodegenerative Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Neurodegenerative Disease Market Share by Type (2018-2029)
Figure 40. Asia Neurodegenerative Disease Market Share by Application (2018-2029)
Figure 41. Asia Neurodegenerative Disease Market Share by Region (2018-2029)
Figure 42. Japan Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 52. Brazil Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Neurodegenerative Disease Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 59. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 60. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 61. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 62. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 63. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 64. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 65. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 67. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 68. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 69. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 70. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 71. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 72. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 73. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 74. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 75. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 76. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2018-2024)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries